Company profile: INmune Bio
1.1 - Company Overview
Company description
- Provider of immune system-based therapies: XPro, a next-generation inhibitor of soluble TNF to decrease neuroinflammation, in clinical trials for Alzheimer's disease and treatment-resistant depression; INKmune, which primes natural killer cells to kill cancer cells, in clinical trials for metastatic castration-resistant prostate cancer; and INB03, neutralizing soluble TNF to down-regulate immune checkpoint proteins in the tumor microenvironment.
Products and services
- INB03: A tumor microenvironment-targeted therapy that neutralizes soluble TNF to down-regulate immune checkpoint proteins, aiming to treat cancers by modulating local immune resistance mechanisms
- INKmune: A clinical-stage therapy that primes a patient’s NK cells to recognize, target, and kill cancer cells, with ongoing trials in metastatic castration-resistant prostate cancer
- XPro: A next-generation TNF inhibitor that specifically neutralizes soluble TNF to decrease neuroinflammation, with clinical trials in Alzheimer’s disease and treatment-resistant depression
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to INmune Bio
Marker Therapeutics
HQ: United States
Website
- Description: Provider of a clinical-stage, non-genetically engineered multi-antigen T cell therapy platform. Offers MT-401 for post-transplant AML, MultiTAA technology, and conducts ARTEMIS and APOLLO trials for blood and solid tumors. Utilizes a manufacturing process expanding natural T cells to target up to five tumor-associated antigens, with therapies designed for quick outpatient administration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marker Therapeutics company profile →
Magenta Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapeutics that unlock the power of stem cell biology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Magenta Therapeutics company profile →
Cell Design Labs
HQ: United States
Website
- Description: Provider of biotherapeutic, cell-based therapy development for cancer and other devastating diseases, leveraging the body's immune system to create smart, living therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cell Design Labs company profile →
TreeFrog Therapeutics
HQ: France
Website
- Description: Provider of a proprietary end-to-end 3D scalable stem cell technology platform to secure cell production and quality, fasten clinical development, facilitate market access, and reduce treatment costs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TreeFrog Therapeutics company profile →
HemoGenyx Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of cell-based and antibody immunotherapies for blood diseases. Offerings include HEMO-CAR-T, a modified T-cell therapy for Acute Myeloid Leukemia (AML); CDX, a bispecific monoclonal antibody for relapsed/refractory AML and conditioning for bone marrow transplantation; and CBR, an immunotherapy platform to prevent and combat viral infections and certain cancers, with proof of concept for SARS-COV-2.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HemoGenyx Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for INmune Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to INmune Bio
2.2 - Growth funds investing in similar companies to INmune Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for INmune Bio
4.2 - Public trading comparable groups for INmune Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →